JP2014507476A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014507476A5 JP2014507476A5 JP2013557816A JP2013557816A JP2014507476A5 JP 2014507476 A5 JP2014507476 A5 JP 2014507476A5 JP 2013557816 A JP2013557816 A JP 2013557816A JP 2013557816 A JP2013557816 A JP 2013557816A JP 2014507476 A5 JP2014507476 A5 JP 2014507476A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- uric acid
- gout
- composition according
- hyperuricemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 201000005569 Gout Diseases 0.000 claims 7
- 201000001431 Hyperuricemia Diseases 0.000 claims 5
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims 5
- 229940116269 uric acid Drugs 0.000 claims 5
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims 4
- TYNLGDBUJLVSMA-UHFFFAOYSA-N 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid Chemical compound O=C1C2=CC(C(O)=O)=CC(OC(C)=O)=C2C(=O)C2=C1C=CC=C2OC(=O)C TYNLGDBUJLVSMA-UHFFFAOYSA-N 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims 2
- 206010029148 Nephrolithiasis Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229960004590 diacerein Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 206010015150 Erythema Diseases 0.000 claims 1
- 208000000913 Kidney Calculi Diseases 0.000 claims 1
- 102000004316 Oxidoreductases Human genes 0.000 claims 1
- 108090000854 Oxidoreductases Proteins 0.000 claims 1
- 206010046337 Urate nephropathy Diseases 0.000 claims 1
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 claims 1
- 201000001509 acute urate nephropathy Diseases 0.000 claims 1
- 230000003113 alkalizing effect Effects 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 229960001338 colchicine Drugs 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000029142 excretion Effects 0.000 claims 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims 1
- 229960002297 fenofibrate Drugs 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 230000002934 lysing effect Effects 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 208000019808 uric acid nephrolithiasis Diseases 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161451600P | 2011-03-11 | 2011-03-11 | |
| US61/451,600 | 2011-03-11 | ||
| PCT/US2012/027993 WO2012125359A1 (en) | 2011-03-11 | 2012-03-07 | Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014507476A JP2014507476A (ja) | 2014-03-27 |
| JP2014507476A5 true JP2014507476A5 (enExample) | 2015-04-23 |
| JP6012639B2 JP6012639B2 (ja) | 2016-10-25 |
Family
ID=46796094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013557816A Expired - Fee Related JP6012639B2 (ja) | 2011-03-11 | 2012-03-07 | 高尿酸血症および高尿酸血症関連代謝障害を治療するための方法および組成物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8865689B2 (enExample) |
| EP (1) | EP2683372B1 (enExample) |
| JP (1) | JP6012639B2 (enExample) |
| KR (1) | KR101567885B1 (enExample) |
| CN (1) | CN103429236B (enExample) |
| AR (1) | AR085662A1 (enExample) |
| AU (1) | AU2012229443B2 (enExample) |
| BR (1) | BR112013022332A2 (enExample) |
| CA (1) | CA2829101C (enExample) |
| ES (1) | ES2634562T3 (enExample) |
| IL (1) | IL228030B (enExample) |
| MX (1) | MX350666B (enExample) |
| PT (1) | PT2683372T (enExample) |
| RU (1) | RU2603050C2 (enExample) |
| TW (1) | TWI505827B (enExample) |
| WO (1) | WO2012125359A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ602583A (en) * | 2010-04-08 | 2014-10-31 | Twi Biotechnology Inc | Methods of using diacerein as an adjunctive therapy for diabetes |
| JP6012639B2 (ja) | 2011-03-11 | 2016-10-25 | ティダブリューアイ・バイオテクノロジー・インコーポレイテッドＴＷＩ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． | 高尿酸血症および高尿酸血症関連代謝障害を治療するための方法および組成物 |
| CN103638020A (zh) * | 2013-12-20 | 2014-03-19 | 中美华世通生物医药科技（武汉）有限公司 | 一种治疗痛风的新型药物组合物 |
| CN104491839B (zh) * | 2014-11-27 | 2016-06-22 | 青岛大学附属医院 | 丝氨酸蛋白酶抑制剂b3用于治疗痛风性肾病的用途 |
| KR101647348B1 (ko) * | 2014-12-30 | 2016-08-22 | 충남대학교산학협력단 | Shp를 유효성분으로 하는 통풍 예방 및 치료용 조성물 |
| US20160303050A1 (en) * | 2015-04-20 | 2016-10-20 | Twi Biotechnology, Inc. | Formulations containing diacerein and methods of lowering blood levels of uric acid using the same |
| BR112017022509A2 (pt) * | 2015-04-20 | 2018-07-17 | Oscar Brown Carl Iii | formulações contendo diacereína e métodos de redução dos níveis sanguíneos de ácido úrico usando as mesmas |
| TWI684465B (zh) * | 2015-04-22 | 2020-02-11 | 安成生物科技股份有限公司 | 含雙醋瑞因之製劑及使用其於降低尿酸血中濃度的方法 |
| CN107921013A (zh) | 2015-07-01 | 2018-04-17 | 安成生物科技股份有限公司 | 双醋瑞因或大黄酸局部用制剂及其用途 |
| MX2018002049A (es) * | 2015-08-17 | 2018-06-15 | Twi Biotechnology Inc | Diacereina o sus analogos para inhibir la expresion de proteina como mota relacionada a la apoptosis que contiene un dominio de reclutamiento de caspasa (asc), expresion de dominios de pirina y familia nlr que contienen 3 (nlrp3) y/o formacion de complejo de inflamasoma de nlrp3. |
| KR101863604B1 (ko) * | 2016-04-08 | 2018-06-04 | 한국 한의학 연구원 | 익지 추출물을 유효성분으로 함유하는 고요산혈증 또는 고요산혈증 관련 대사 장애의 예방, 개선 또는 치료용 조성물 |
| TW201739448A (zh) * | 2016-05-06 | 2017-11-16 | 安成生物科技股份有限公司 | 用於治療及/或預防血液相關疾病之方法及配方 |
| CN107468955B (zh) * | 2017-09-06 | 2020-07-24 | 大连医科大学 | 治疗痛风性关节炎的中药及制备方法 |
| KR102361526B1 (ko) * | 2019-07-02 | 2022-02-11 | 한국 한의학 연구원 | 난각막을 유효성분으로 함유하는 고요산혈증 또는 고요산혈증 관련 대사 장애의 예방, 개선 또는 치료용 조성물 |
| CN113082012A (zh) * | 2021-04-26 | 2021-07-09 | 北京亿药科技有限公司 | 紫苏烯在制备预防和/或治疗高尿酸血症药物中的应用 |
| US12269875B2 (en) * | 2023-08-03 | 2025-04-08 | Jeff R. Peterson | Gout flare prevention methods using IL-1BETA blockers |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04009698A (es) * | 2004-10-04 | 2006-04-05 | Maria Elena Garcia Armenta | Formulaciones farmaceuticas solidas conteniendo diacereina y meloxicam. |
| PL2124997T3 (pl) | 2006-10-20 | 2013-01-31 | Regeneron Pharma | Zastosowanie antagonistów IL-1 do leczenia dny moczanowej i dny rzekomej |
| US7632490B2 (en) * | 2006-10-20 | 2009-12-15 | Regeneron Pharmaceuticals, Inc. | Use of IL-1 antagonists to treat gout |
| ES2560899T3 (es) * | 2007-09-14 | 2016-02-23 | Wockhardt Limited | Composiciones de diacereína |
| WO2010003092A1 (en) | 2008-07-03 | 2010-01-07 | University Of Massachusetts | Methods and compositions for reducing inflammation and treating inflammatory disorders |
| TWI473610B (zh) * | 2008-10-28 | 2015-02-21 | Twi Biotechnology Inc | 包含雙醋瑞因（ｄｉａｃｅｒｅｉｎ）之醫藥組合物 |
| JP6012639B2 (ja) | 2011-03-11 | 2016-10-25 | ティダブリューアイ・バイオテクノロジー・インコーポレイテッドＴＷＩ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． | 高尿酸血症および高尿酸血症関連代謝障害を治療するための方法および組成物 |
-
2012
- 2012-03-07 JP JP2013557816A patent/JP6012639B2/ja not_active Expired - Fee Related
- 2012-03-07 CN CN201280012914.9A patent/CN103429236B/zh not_active Expired - Fee Related
- 2012-03-07 AU AU2012229443A patent/AU2012229443B2/en not_active Ceased
- 2012-03-07 CA CA2829101A patent/CA2829101C/en not_active Expired - Fee Related
- 2012-03-07 MX MX2013010384A patent/MX350666B/es active IP Right Grant
- 2012-03-07 EP EP12757767.4A patent/EP2683372B1/en not_active Not-in-force
- 2012-03-07 RU RU2013145498/14A patent/RU2603050C2/ru not_active IP Right Cessation
- 2012-03-07 WO PCT/US2012/027993 patent/WO2012125359A1/en not_active Ceased
- 2012-03-07 US US13/414,264 patent/US8865689B2/en not_active Expired - Fee Related
- 2012-03-07 KR KR1020137026784A patent/KR101567885B1/ko not_active Expired - Fee Related
- 2012-03-07 BR BR112013022332A patent/BR112013022332A2/pt not_active IP Right Cessation
- 2012-03-07 ES ES12757767.4T patent/ES2634562T3/es active Active
- 2012-03-07 PT PT127577674T patent/PT2683372T/pt unknown
- 2012-03-09 TW TW101108193A patent/TWI505827B/zh not_active IP Right Cessation
- 2012-03-12 AR ARP120100799A patent/AR085662A1/es unknown
-
2013
- 2013-08-19 IL IL228030A patent/IL228030B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014507476A5 (enExample) | ||
| RU2013145498A (ru) | Способы и композиции для лечения гиперурикемии и метаболических нарушений, связанных с гиперурикемией | |
| Yang et al. | The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer’s disease | |
| EA201790406A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| CR10455A (es) | Compuestos farmaceuticos | |
| JP2017513836A5 (enExample) | ||
| EA201490279A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| HK1206264A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2017505285A5 (enExample) | ||
| AR082167A1 (es) | Formas de dosificacion gastrorretentivas | |
| JP2020500875A5 (enExample) | ||
| AR059575A1 (es) | Metodo para el tratamiento de enfermedades inflamatorias | |
| EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| AR075179A1 (es) | Formulaciones galenicas de compuestos organicos que comprenden alisquireno | |
| JP2009138003A5 (enExample) | ||
| JP2013209384A5 (enExample) | ||
| NZ625592A (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| HRP20171743T1 (hr) | Sastavi i postupci za savladavanje otpornosti na tramadol | |
| JP2018533560A5 (enExample) | ||
| MA37455A1 (fr) | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique | |
| JP2016512817A5 (enExample) | ||
| JP2017508817A5 (enExample) | ||
| EP2796450A4 (en) | 6-AMINOPYRIDIN-3-OL DERIVATIVES OR PHARMACEUTICAL SALTS AND / OR PHARMACEUTICAL COMPOSITION THEREOF AS ACTIVE AGENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | |
| JP2014504636A5 (enExample) | ||
| RU2018146504A (ru) | Лечение внутрипеченочных холестатических заболеваний |